59.50 +2.88 (5.09%)
Pre-Market: 9:13AM EDT
|Bid||57.00 x 900|
|Ask||59.39 x 1100|
|Day's Range||55.86 - 56.94|
|52 Week Range||26.40 - 74.81|
|Beta (3Y Monthly)||-0.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.85|
- Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes ABBOTT PARK, Ill. and SAN DIEGO , Oct. ...
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, plans to release its third quarter 2019 results after the financial markets close on Monday, November 4, 2019.
Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced publication of real-world data from more than 8,000 users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend technology in the medical journal Diabetes Technology and Therapeutics. The results demonstrate sustained reductions in hypoglycemia across all groups using Basal-IQ technology, regardless of prior therapy. A specific sub-analysis of t:slim X2 pump users who remotely updated their pump software to Basal-IQ technology revealed a 45 percent relative risk reduction in hypoglycemia and a 71 percent relative risk reduction of hypoglycemic events.
PRESIDENT & CEO of Tandem Diabetes Care Inc (30-Year Financial, Insider Trades) John F Sheridan (insider trades) sold 9,538 shares of TNDM on 09/06/2019 at an average price of $70.03 a share. Continue reading...
Every investor in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) should be aware of the most powerful shareholder groups...
Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).
EVP & CHIEF COMMERCIAL OFFICER of Tandem Diabetes Care Inc (30-Year Financial, Insider Trades) Brian B Hansen (insider trades) sold 15,000 shares of TNDM on 08/12/2019 at an average price of $62.97 a share. Continue reading...
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
In his final "Executive Decision" segment of Mad Money Wednesday night, Jim Cramer also checked in with Kim Blickenstaff, executive chairman at Tandem Diabetes Care , which posted strong earnings last week that sent shares up over 8% before giving back much of those gains by the close. Blickenstaff blamed the sudden reversal in their shares on global uncertainty. Currently, only 30% of Type 1 diabetes patients are using a pump, Blickenstaff said, leaving a lot of room for growth for Tandem.
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
The medical device company got oh-so-close to erasing operating losses in Q2, but second-half growth will finally put the business in the black.
Today we will run through one way of estimating the intrinsic value of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by...